001019089 001__ 1019089
001019089 005__ 20240116084327.0
001019089 0247_ $$2doi$$a10.1002/hbm.26206
001019089 0247_ $$2ISSN$$a1065-9471
001019089 0247_ $$2ISSN$$a1097-0193
001019089 0247_ $$2datacite_doi$$a10.34734/FZJ-2023-05142
001019089 0247_ $$2pmid$$a36649260
001019089 0247_ $$2WOS$$aWOS:000987490900001
001019089 037__ $$aFZJ-2023-05142
001019089 082__ $$a610
001019089 1001_ $$0P:(DE-HGF)0$$aPremi, Enrico$$b0
001019089 245__ $$aUnravelling neurotransmitters impairment in primary progressive aphasias
001019089 260__ $$aNew York, NY$$bWiley-Liss$$c2023
001019089 3367_ $$2DRIVER$$aarticle
001019089 3367_ $$2DataCite$$aOutput Types/Journal article
001019089 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1702546058_9248
001019089 3367_ $$2BibTeX$$aARTICLE
001019089 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001019089 3367_ $$00$$2EndNote$$aJournal Article
001019089 520__ $$aPrimary progressive aphasias (PPAs) are a group of neurodegenerative diseases mainly characterized by language impairment, and with variably presence of dysexecutive syndrome, behavioural disturbances and parkinsonism. Detailed knowledge of neurotransmitters impairment and its association with clinical features hold the potential to develop new tailored therapeutic approaches. In the present study, we applied JuSpace toolbox, which allowed for cross-modal correlation of magnetic resonance imaging (MRI)-based measures with nuclear imaging derived estimates covering various neurotransmitter systems including dopaminergic, serotonergic, noradrenergic, GABAergic and glutamatergic neurotransmission. We included 103 PPA patients and 80 age-matched healthy controls (HC). We tested if the spatial patterns of grey matter volume (GMV) alterations in PPA patients (relative to HC) are correlated with specific neurotransmitter systems. As compared to HC, voxel-based brain changes in PPA were significantly associated with spatial distribution of serotonin, dopamine, and glutamatergic pathways (p < .05, False Discovery Rate corrected-corrected). Disease severity was negatively correlated with the strength of GMV colocalization of D1 receptors (p = .035) and serotonin transporter (p = .020). Moreover, we observed a significant negative correlation between positive behavioural symptoms, as measured with Frontal Behavioural Inventory, and GMV colocalization of D1 receptors (p = .007) and serotonin transporter (p < .001). This pilot study suggests that JuSpace is a helpful tool to indirectly assess neurotransmitter deficits in neurodegenerative dementias and may provide novel insight into disease mechanisms and associated clinical features.
001019089 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001019089 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001019089 7001_ $$0P:(DE-Juel1)177772$$aDukart, Juergen$$b1
001019089 7001_ $$0P:(DE-HGF)0$$aMattioli, Irene$$b2
001019089 7001_ $$0P:(DE-HGF)0$$aLibri, Ilenia$$b3
001019089 7001_ $$0P:(DE-HGF)0$$aPengo, Marta$$b4
001019089 7001_ $$0P:(DE-HGF)0$$aGadola, Yasmine$$b5
001019089 7001_ $$0P:(DE-HGF)0$$aCotelli, Maria$$b6
001019089 7001_ $$0P:(DE-HGF)0$$aManenti, Rosa$$b7
001019089 7001_ $$0P:(DE-HGF)0$$aBinetti, Giuliano$$b8
001019089 7001_ $$0P:(DE-HGF)0$$aGazzina, Stefano$$b9
001019089 7001_ $$0P:(DE-HGF)0$$aAlberici, Antonella$$b10
001019089 7001_ $$0P:(DE-HGF)0$$aMagoni, Mauro$$b11
001019089 7001_ $$0P:(DE-HGF)0$$aKoch, Giacomo$$b12
001019089 7001_ $$0P:(DE-HGF)0$$aGasparotti, Roberto$$b13
001019089 7001_ $$0P:(DE-HGF)0$$aPadovani, Alessandro$$b14
001019089 7001_ $$0P:(DE-HGF)0$$aBorroni, Barbara$$b15$$eCorresponding author
001019089 773__ $$0PERI:(DE-600)1492703-2$$a10.1002/hbm.26206$$gVol. 44, no. 6, p. 2245 - 2253$$n6$$p2245 - 2253$$tHuman brain mapping$$v44$$x1065-9471$$y2023
001019089 8564_ $$uhttps://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.pdf$$yOpenAccess
001019089 8564_ $$uhttps://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.gif?subformat=icon$$xicon$$yOpenAccess
001019089 8564_ $$uhttps://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001019089 8564_ $$uhttps://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001019089 8564_ $$uhttps://juser.fz-juelich.de/record/1019089/files/Human%20Brain%20Mapping%20-%202023%20-%20Premi%20-%20Unravelling%20neurotransmitters%20impairment%20in%20primary%20progressive%20aphasias.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001019089 909CO $$ooai:juser.fz-juelich.de:1019089$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001019089 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177772$$aForschungszentrum Jülich$$b1$$kFZJ
001019089 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Barbara Borroni, Clinica Neurologica, Università degli Studi di Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy.$$b15
001019089 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001019089 9141_ $$y2023
001019089 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-27T20:46:01Z
001019089 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-25$$wger
001019089 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
001019089 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
001019089 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHUM BRAIN MAPP : 2022$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-08-25$$wger
001019089 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-27T20:46:01Z
001019089 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001019089 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
001019089 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-09-27T20:46:01Z
001019089 920__ $$lno
001019089 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
001019089 980__ $$ajournal
001019089 980__ $$aVDB
001019089 980__ $$aUNRESTRICTED
001019089 980__ $$aI:(DE-Juel1)INM-7-20090406
001019089 9801_ $$aFullTexts